BioCentury
ARTICLE | Clinical News

Patient receives glioblastoma vaccine under right to try

January 11, 2019 6:11 PM UTC

ERC-USA and the University of California Irvine announced that a patient with recurrent glioblastoma multiforme is receiving therapeutic vaccine ERC1671 under California's right-to-try (RTT) law.

ERC1671 is in a U.S. Phase II trial as part of a once-monthly combination treatment for recurrent GBM and gliosarcoma. The patient, who did not qualify for enrollment in that trial, began receiving ERC1671 in November under RTT. ERC-USA did not respond in time for publication to inquiries regarding why the patient applied for RTT instead of using FDA's expanded access program...